 | • レポートコード：MRC2303K003 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、164ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、2021年に21,128.13百万ドルであった世界の製剤開発アウトソーシング市場規模が、予測期間中（2022年-2027年）、CAGR 6.42％で増大し、2027年には31,974.84百万ドルへ及ぶと予測されています。本レポートでは、製剤開発アウトソーシングの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、サービス別（前処方化サービス、処方最適化）分析、剤形別（注射、経口、外用、その他）分析、用途別（腫瘍、遺伝性疾患、神経内科、感染症、その他）分析、エンドユーザー別（医薬品・バイオ医薬品企業、政府・学術機関）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Charles River Laboratories、Aizant Drug Research Solutions Private Limited、Catalent Inc.、Laboratory Corporation of America Holdings、Syngene International Ltd、Irisys LLC、Intertek Group PLC、Piramal Pharma Solutions、Qiotient Sciences、Patheon (Thermo Fisher Scientific Inc.)、Emergent BioSolutions Inc.、Lonza Group AG、Dr. Reddy's Laboratories Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の製剤開発アウトソーシング市場規模：サービス別 - 前処方化サービスの市場規模 - 処方最適化の市場規模 ・世界の製剤開発アウトソーシング市場規模：剤形別 - 注射製剤開発アウトソーシングの市場規模 - 経口製剤開発アウトソーシングの市場規模 - 外用製剤開発アウトソーシングの市場規模 - その他製剤開発アウトソーシングの市場規模 ・世界の製剤開発アウトソーシング市場規模：用途別 - 腫瘍における市場規模 - 遺伝性疾患における市場規模 - 神経内科における市場規模 - 感染症における市場規模 - その他用途における市場規模 ・世界の製剤開発アウトソーシング市場規模：エンドユーザー別 - 医薬品・バイオ医薬品企業における市場規模 - 政府・学術機関における市場規模 ・世界の製剤開発アウトソーシング市場規模：地域別 - 北米の製剤開発アウトソーシング市場規模 アメリカの製剤開発アウトソーシング市場規模 カナダの製剤開発アウトソーシング市場規模 メキシコの製剤開発アウトソーシング市場規模 … - ヨーロッパの製剤開発アウトソーシング市場規模 ドイツの製剤開発アウトソーシング市場規模 イギリスの製剤開発アウトソーシング市場規模 フランスの製剤開発アウトソーシング市場規模 … - アジア太平洋の製剤開発アウトソーシング市場規模 中国の製剤開発アウトソーシング市場規模 日本の製剤開発アウトソーシング市場規模 インドの製剤開発アウトソーシング市場規模 … - 南米/中東の製剤開発アウトソーシング市場規模 ブラジルの製剤開発アウトソーシング市場規模 アルゼンチンの製剤開発アウトソーシング市場規模 サウジアラビアの製剤開発アウトソーシング市場規模 ・競争状況 ・市場機会・将来動向 |
The formulation development outsourcing market was valued at approximately USD 21,128.13 million in 2021, and it is expected to reach USD 31,974.84 million in 2027, with a CAGR of 6.42% over the forecast period, 2022-2027.
Amid the COVID-19 pandemic, countries’ health systems are rapidly investing in research and development to combat the virus, having a significant impact on the formulation development outsourcing market. For instance, in October 2020, AiPharma joined a global consortium of pharmaceutical, manufacturing, and distribution leaders to advance oral antiviral Avigan/Reeqomus for COVID-19. As a part of the consortium, AiPharma commercializes all formulations of favipiravir, a broad spectrum oral antiviral drug that targets COVID-19 and 11 other infectious diseases. Thus, the onset of the pandemic has significantly benefitted the formulation development outsourcing market. Moreover, as per an article titled “Pharmaceutical Technology, 2021 Outsourcing Resources Supplement”, published in August 2021, the pharmaceutical outsourcing market has seen a growth in vaccine development and manufacturing activity in the past year, particularly due to the industry’s response to the COVID-19 pandemic. As a result of which, there has been an increase in the formulation development outsourcing activities, thereby contributing to the market growth.
Furthermore, the major factors fueling the market growth are the increasing trend of patent protection expiration of major drugs and the rising number of pharmaceutical and biopharmaceutical companies outsourcing their services. The increasing trend of patent protection expiration of major drugs is driving the market growth. For instance, as per a 2021 update by the Generics and Biosimilar Initiative, as part of ongoing action to improve the quality of generics and ensure an efficient and competitive generics market, the Korean Ministry of Food and Drug Safety (MFDS) announced that 158 patents for pharmaceutical products were anticipated to expire in 2021. As per the same source, the MFDS’s Green List (a list similar to the US Food and Drug Administration’s (FDA) Orange Book) shows that 44 of the patents will be ready for immediate generics entry, having no other patents on the products involved. Thus, this increases the need for formulation development outsourcing for newer candidates, thereby contributing to the market growth.
However, structural changes in the pharmaceutical industry and insufficient funding to perform the drug development process through formulation development are the major factors hindering the market growth.
Formulation Development Outsourcing Market Trends
The Oncology Segment is Expected to Witness Significant Growth over the Forecast Period
By application, the oncology segment is anticipated to hold a major share of the market. This can be attributed to the rising incidence rates of cancer cases globally. According to the World Health Organization (WHO), cancer accounted for approximately 10 million deaths in 2020. Additionally, as per the 2021 statistics by the American Cancer Society, by 2040, the global burden of cancer is expected to grow to 27.5 million new cases and 16.3 million cancer deaths.
Formulation development plays a vital role in anti-cancer drugs, as formulation issues, including stability, solubility, and bioavailability, are important considerations for the drug development process. Hence, most pharma service companies are focused on oncology formulation development to provide end-to-end solutions for oncology drug development. For instance, in November 2021, Oncology Pharma Inc. revealed plans for the development of a lead drug candidate in a co-development project with NanoSmart Pharmaceuticals Inc. Likewise, in October 2021, Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma entered a development and manufacturing agreement with ESSA Pharmaceuticals. Metrics will provide formulation development, analytical services, and manufacturing to support the ongoing clinical development of an orally administered oncology drug as a part of the agreement.
Thus, the high incidence rates of cancer cases and the increasing focus on cancer therapeutics by biopharmaceutical companies are expected to aid in the growth of the segment over the forecast period.
North America is Expected to Hold Significant Market Share over the Forecast Period
Within North America, the United States is expected to hold a major share of the market. This can be attributed to the growing burden of chronic diseases and the presence of key players in the region, especially in the United States. As most of the major drugs are in the stage of patent expiration, key players are involved in novel drug development. In this context, to save time and investment on a series of clinical trials and evaluation studies in formulation development, pharmaceutical companies are outsourcing formulation development services to CROs, which may drive market growth in the region.
Additionally, amid the COVID-19 pandemic, several collaborative research programs are looking to fast-track their process in terms of advancing therapeutics and vaccines by collaborating with institutions, such as the Biomedical Advanced Research and Development Authority (BARDA) and Coalition for Epidemic Preparedness Innovations (CEPI). For instance, in May 2020, the United States Department of Commerce’s National Institute of Standards and Technology (NIST) funded around USD 8.9 million to the highly impacted biopharmaceutical manufacturing projects in response to the emerged outbreak. Therefore, such initiatives are contributing to the increasing outsourcing for formulation development, thereby contributing to the market growth.
Moreover, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in January 2022, Recro Pharma Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, reported being awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government.
Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Formulation Development Outsourcing Market Competitor Analysis
The formulation development outsourcing market is moderately competitive. In terms of market share, a few companies, such as Charles River Laboratories, Aizant Drug Research Solutions Private Limited, Catalent Inc., Laboratory Corporation of America Holdings, and Syngene International Ltd, among others, hold the largest market shares. Key market players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand their global product portfolios and secure their positions in the global market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Trend of Patent Protection Expiration of Major Drugs
4.2.2 Rising Number of Pharmaceutical and Biopharmaceutical Companies Outsourcing Their Services
4.3 Market Restraints
4.3.1 Structural Changes in the Pharmaceutical Industry
4.3.2 Insufficient Funding to Perform the Drug Development Process Through Formulation Development
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Service
5.1.1 Pre-formulation Services
5.1.1.1 Discovery and Preclinical Services
5.1.1.2 Analytical Services
5.1.2 Formulation Optimization
5.1.2.1 Phase I
5.1.2.2 Phase II
5.1.2.3 Phase III
5.1.2.4 Phase IV
5.2 By Dosage Form
5.2.1 Injectable
5.2.2 Oral
5.2.3 Topical
5.2.4 Other Dosage Forms
5.3 By Application
5.3.1 Oncology
5.3.2 Genetic Disorders
5.3.3 Neurology
5.3.4 Infectious Diseases
5.3.5 Respiratory
5.3.6 Cardiovascular
5.3.7 Other Applications
5.4 By End User
5.4.1 Pharmaceutical and Biopharmaceutical Companies
5.4.2 Government and Academic Institutes
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Charles River Laboratories
6.1.2 Aizant Drug Research Solutions Private Limited
6.1.3 Catalent Inc.
6.1.4 Laboratory Corporation of America Holdings
6.1.5 Syngene International Ltd
6.1.6 Irisys LLC
6.1.7 Intertek Group PLC
6.1.8 Piramal Pharma Solutions
6.1.9 Qiotient Sciences
6.1.10 Patheon (Thermo Fisher Scientific Inc.)
6.1.11 Emergent BioSolutions Inc.
6.1.12 Lonza Group AG
6.1.13 Dr. Reddy’s Laboratories Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS